Atara Biotherapeutics to present clinical results of Car T platform
Category: #health  By Pankaj Singh  Date: 2019-03-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Atara Biotherapeutics to present clinical results of Car T platform
  • The firm is looking forward to its MSK collaborators’ clinical outcomes of a mesothelin-targeted autologous CAR T for patients suffering from advanced malignant pleural ailment
     
  • The event is slated to be held from March 29 to April 3 at Atlanta, Georgia

Atara Biotherapeutics, Inc. has reportedly declared that it would present the clinical safety and efficacy results of mesothelin-targeted CAR T and next-generation CAR T platform at the annual meeting of the American Association of Cancer Research (AACR). As per trusted sources, the clinical results are from Memorial Sloan Kettering Cancer Center.

According to a press release from Atara Biotherapeutics, the event is slated to be held from March 29 to April 3 at Atlanta, Georgia. For the record, Mesothelin is a solid tumor-related antigen which is expressed at higher levels on the surface of cells in hostile solid tumors including non-small cell lung cancer, pancreatic cancer, ovarian cancer, triple-negative breast cancer, and mesothelioma.

Global Head of Research and Development at Atara Biotherapeutics, Dietmar Berger, M.D., Ph.D. was reportedly quoted saying that the company has established one of the foremost CAR T portfolios. The pre-clinical results presented at the AACR show are encouraging and show the potential of the firm’s EBV-specific T cell platform to develop allogeneic, off-the-shelf CAT T immunotherapies, Berger further added.

Reportedly, Atara Biotherapeutics is looking forward to its MSK collaborators’ clinical outcomes of a mesothelin-targeted autologous CAR T to treat patients suffering from advanced malignant pleural ailment.

Preliminary outcomes from the MSK sponsored Stage 1 study (currently in progress) of a mesothelin-targeted CAR T immunotherapy for patients with malignant plural cancers were exhibited at the 2018 annual meeting of American Society of Gene and Cell Therapy.

Atara had signed an exclusive collaboration and license deal with MSK in Jan this year to create a mesothelin-targeted CAR T by utilizing PD-1 dominant negative receptor (DNR) and 1XX CAR signaling domain checkpoint inhibition technologies.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Covid-19 could end in Europe after the Omicron wave, says WHO
Covid-19 could end in Europe after the Omicron wave, says WHO
By Pankaj Singh

The new Omicron variant has shifted the pandemic into a new phase and could end in Europe, claims WHO Europe Director Hans Kluge recently. Mr. Kluge told sources that it could be possible that the region is heading towards a pandemic endgame, adding...

Scotland scientists develop AI-based test using X-rays to detect COVID-19
Scotland scientists develop AI-based test using X-rays to detect COVID-19
By Pankaj Singh

Scientists in Scotland have reportedly created an AI (artificial intelligence) based test that detects COVID-19,accurately, using X-rays in just a few minutes. The testing platform, developed at the University of the West of Scotland (UWS), can detec...

STG announces launch of Trellix; aims for technological innovation
STG announces launch of Trellix; aims for technological innovation
By Pankaj Singh

Symphony Technology Group (STG), an American private equity firm, has recently announced the launch of Trellix. This innovative business will be bringing prolonged XDR (detection and response) to firms while focusing on fastening technology innovatio...